Early Ambulation After Adductor Canal Block for Total Knee Arthroplasty

Pain Clinical Trial

Official title:

Assessment of Early Ambulation in Patients Receiving Continuous Adductor Canal Block With Ultrasound Guided Posterior Capsular Knee Injection vs. Femoral Nerve Block With Tibial Nerve Block Following Total Knee Replacement

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01459861
• Other study ID #: 11-09-003
• Status: Terminated
• Phase: N/A
• First received: October 6, 2011
• Last updated: March 4, 2013
• Start date: October 2011
• Est. completion date: September 2012

Study information

• Verified date: February 2013
• Source: Saint Francis Care
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess early ambulation following total knee replacement in patients receiving continuous adductor canal block with posterior capsular injection compared to continuous femoral nerve block with tibial nerve block.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• knee arthroplasty

• ages 18-80

Exclusion Criteria:

• history of neurological disease

• diabetes

• pregnancy

• neuropathy

• chronic narcotic use

• allergy to local anesthetic solution or NSAIDS

• inability to give consent or cooperate with the study protocol

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoarthritis
• Pain

Intervention

Procedure:
• Canal Block and Capsular Injection
Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.
• Femoral Nerve Block with Tibial Nerve Block
Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.

Locations

Country	Name	City	State
United States	Saint Francis Hospital and Medical Center	Hartford	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Saint Francis Care

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ability to ambulate post operatively.	Ability to ambulate and perform tasks of the rehabilitation program and reach rehabilitation milestones after total knee arthroplasty.	Up to 3 days (72 hours) post surgery.	No
Secondary	Pain scores at rest and with knee flexion.	Measures of pain score using numeric pain rating scale (0=no pain, 10=worst pain) completed by patient in recovery room and every 6 hours for a 72 hour period after discharge from recovery room.	Up to 3 days ( 72 hours) after surgery	No
Secondary	Pain Medication Consumption	Amount of opioid consumption post surgery for 72 hours.	Up to 3 days (72 hours) post surgery	No